|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61P 35/02 | (2018.01) |
| (11) | Number of the document | 3600326 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18718926.1 |
| Date of filing the European patent application | 2018-03-29 | |
| (97) | Date of publication of the European application | 2020-02-05 |
| (45) | Date of publication and mention of the grant of the patent | 2023-01-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2018/052187 |
| Date | 2018-03-29 |
| (87) | Number | WO 2018/178925 |
| Date | 2018-10-04 |
| (30) | Number | Date | Country code |
| 201762479397 P | 2017-03-31 | US |
| (72) |
FERRETTI, Stephane , CH
GUERREIRO, Nelson , CH
JEAY, Sebastien , CH
JULLION, Astrid , CH
MEILLE, Christophe , CH
WUERTHNER, Jens , CH
FABRE, Claire , CH
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | DOSE AND REGIMEN FOR AN HDM2-P53 INTERACTION INHIBITOR IN HEMATOLOGICAL TUMORS |
| DOSE AND REGIMEN FOR AN HDM2-P53 INTERACTION INHIBITOR IN HEMATOLOGICAL TUMORS |